Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Application of IFN-γ-Licensed urine-derived stem cells in SIS hydrogel promotes scar-free wound healing by immunomodulation and microenvironment remodeling

Nie R., Zhang QY., Feng ZY., Tan J., Huang K., Xu N.

Animal Study on Chronic Wound, Scar, Chronic Inflammation, Immune Modulation, published in Bioact Mater (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Bioact Mater (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41675148
PMCID
PMC12886089
DOI
10.1016/j.bioactmat.2025.12.010

Abstract (original English)

Scar-free wound healing remains an unmet clinical imperative, as dysregulated immune microenvironment during tissue repair drives irreversible fibrosis. While existing treatments (corticosteroid injections, laser therapy, surgical excision) provide symptomatic relief, they fail to address the pathophysiological triad of fibrosis: persistent fibroblast activation, aberrant ECM deposition, and chronic inflammation. Mesenchymal stem cell (MSC) therapy has emerged as a promising strategy to concurrently target these pathological axes. Among MSC sources, urine-derived stem cells (USCs) stand out as a superior candidate, owing to their non-invasive accessibility, minimal ethical concerns, favorable safety profile, and robust proliferative capacity. In this study, we explored the therapeutic potential of IFN-γ-pretreated urine-derived stem cells (γ-USCs) encapsulated in small intestinal submucosa (SIS) hydrogel for scar-free skin wound healing. Our findings demonstrated that IFN-γ pretreatment potentiated the immunomodulatory properties of USCs, driving macrophage polarization toward an anti-inflammatory phenotype to normalize the wound microenvironment. In vitro, γ-USCs significantly suppressed the hyperactivity of keloid fibroblasts and attenuated TGF-β-induced fibrotic responses, as evidenced by reduced collagen deposition and downregulated fibrotic markers. In vivo, using a rabbit

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research